Breast Cancer Update, Issue 3, 2018


Interview with Joyce O’Shaughnessy, MD

Track 1: Case: A 51-year-old woman presents with ER-positive, HER2-positive metastatic breast cancer (mBC)
Track 2: Potential synergy of neratinib with endocrine therapy or capecitabine for ER-positive, HER2-positive mBC
Track 3: Case: A 56-year-old woman with heavily pretreated HER2-positive mBC develops thrombocytopenia after experiencing a complete response to T-DM1
Track 4: Exceptional clinical responses to HER2-targeted therapies
Track 5: Ongoing investigation of the biologic mechanisms underlying exceptional responses to HER2-targeted therapy
Track 6: Case: A 38-year-old woman with metastatic triple-negative BC (mTNBC) and a PI3KCA mutation achieves an excellent clinical response to irinotecan/carboplatin/cetuximab on a clinical trial
Track 7: Therapeutic approach for patients with ER-positive, HER2-positive mBC
Track 8: Duration of therapy for patients with ER-positive, HER2-positive mBC
Track 9: Use of CDK4/6 inhibitors for patients with ER-positive, HER2-positive BC
Track 10: Activity and side-effect profile of the highly selective tyrosine kinase inhibitor tucatinib in HER2-positive advanced BC
Track 11: Case: A 65-year-old woman with ER/PR-positive, HER2-negative BC receives a 21-gene assay Recurrence Score® (RS) of 24
Track 12: Selection of adjuvant endocrine therapy for premenopausal patients with ER-positive BC
Track 13: Incorporating TAILORx trial results in therapeutic decision-making with the 21-gene RS assay in ER-positive, HER2-negative, node-negative BC
Track 14: Case: A 45-year-old woman with ER-positive, HER2-negative BC and metastases to the liver and bones receives abemaciclib and fulvestrant
Track 15: Efficacy and tolerability of abemaciclib for ER-positive mBC
Track 16: Benefits and risks associated with palbociclib and ribociclib
Track 17: Choice of endocrine therapy to partner with a CDK4/6 inhibitor for ER-positive mBC
Track 18: Promising antibody-drug conjugates under investigation for BC
Track 19: Role of checkpoint inhibitors for patients with mTNBC
Track 20: Indications for BRCA mutation testing in patients with BC
Track 21: Side effects associated with PARP inhibitors
Track 22: Case: A 30-year-old woman with TNBC and a solitary metastasis to the liver receives eribulin and capecitabine
Track 23: Efficacy of eribulin for patients with TNBC
Track 24: Benefits and risks of PI3 kinase inhibitors for BC

Interview with Erica L Mayer, MD, MPH

Track 1: Preliminary results from the Phase III KATHERINE study evaluating T-DM1 versus trastuzumab as adjuvant therapy for patients with HER2-positive early BC and residual disease after preoperative therapy
Track 2: Side effects and quality of life associated with T-DM1 treatment
Track 3: Case: A 57-year-old postmenopausal woman with an ER/PR-positive, HER2-positive infiltrating ductal carcinoma (IDC) and positive axillary lymph nodes achieves a clinical response to neoadjuvant paclitaxel/trastuzumab/pertuzumab (THP)
Track 4: Therapeutic options for patients with ER-positive, HER2-positive BC in the (neo)adjuvant setting
Track 5: Efficacy of CDK4/6 inhibitors for patients with ER-positive, HER2-negative mBC
Track 6: Benefits and risks with the addition of CDK4/6 inhibitors to hormone therapy
Track 7: Perspective on the use of CDK4/6 inhibitors for elderly patients
Track 8: Activity and tolerability of palbociclib, abemaciclib and ribociclib
Track 9: Dosing considerations and adherence to treatment with CDK4/6 inhibitors
Track 10: Activity of CDK4/6 inhibitors in patients with brain metastases
Track 11: Ongoing Phase II PACE study evaluating the addition of palbociclib with or without avelumab to fulvestrant for patients who experience disease progression on a CDK4/6 inhibitor and endocrine therapy
Track 12: Selection and sequencing of CDK4/6 inhibitors for patients with ER-positive, HER2-negative mBC
Track 13: Case: A 58-year-old postmenopausal woman with a Grade III, ER/PR-positive, HER2-negative IDC and a RS of 12
Track 14: Use of the 21-gene RS assay for patients with node-positive BC
Track 15: Choice of endocrine therapy for premenopausal women with node-positive BC
Track 16: Role of chemotherapy for patients with ER-positive, node-positive BC and an intermediate RS
Track 17: Perspective on using genomic assays for ER-positive, HER2-negative, node-negative BC in the neoadjuvant setting
Track 18: IMpassion130: A Phase III trial of atezolizumab with nab paclitaxel as first-line treatment for advanced TNBC
Track 19: Case: A 55-year-old woman with ER/PR-positive, HER2-negative mBC and a germline BRCA2 mutation receives olaparib after disease progression on several lines of therapy
Track 20: Efficacy of the PARP inhibitors talazoparib and olaparib in patients with BC and a germline BRCA mutation
Track 21: Prognosis and outcomes for patients with pregnancy-associated BC
Track 22: Case: A 32-year-old woman who is 12 weeks pregnant presents with a palpable breast mass and is diagnosed with ER-positive, HER2-positive BC
Joyce O’Shaughnessy, MD
Breast Cancer Research Program
Baylor Charles A Sammons
Cancer Center
Celebrating Women Chair in Breast Cancer Research
Texas Oncology
US Oncology
Dallas, Texas
Erica L Mayer, MD, MPH
Senior Physician
Susan F Smith Center for
Women’s Cancers
Dana-Farber Cancer Institute
Assistant Professor in Medicine
Harvard Medical School
Boston, Massachusetts
Neil Love, MD
Research To Practice
Miami, Florida